1. Home
  2. BMRN vs ATI Comparison

BMRN vs ATI Comparison

Compare BMRN & ATI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BMRN
  • ATI
  • Stock Information
  • Founded
  • BMRN 1996
  • ATI 1960
  • Country
  • BMRN United States
  • ATI United States
  • Employees
  • BMRN 3040
  • ATI N/A
  • Industry
  • BMRN Biotechnology: Pharmaceutical Preparations
  • ATI Steel/Iron Ore
  • Sector
  • BMRN Health Care
  • ATI Industrials
  • Exchange
  • BMRN Nasdaq
  • ATI Nasdaq
  • Market Cap
  • BMRN 9.9B
  • ATI 11.2B
  • IPO Year
  • BMRN 1999
  • ATI N/A
  • Fundamental
  • Price
  • BMRN $51.46
  • ATI $97.65
  • Analyst Decision
  • BMRN Buy
  • ATI Strong Buy
  • Analyst Count
  • BMRN 19
  • ATI 7
  • Target Price
  • BMRN $90.26
  • ATI $103.00
  • AVG Volume (30 Days)
  • BMRN 2.9M
  • ATI 1.7M
  • Earning Date
  • BMRN 10-27-2025
  • ATI 10-28-2025
  • Dividend Yield
  • BMRN N/A
  • ATI N/A
  • EPS Growth
  • BMRN 59.53
  • ATI 18.88
  • EPS
  • BMRN 2.68
  • ATI 3.10
  • Revenue
  • BMRN $3,094,001,000.00
  • ATI $4,583,000,000.00
  • Revenue This Year
  • BMRN $13.32
  • ATI $6.53
  • Revenue Next Year
  • BMRN $7.51
  • ATI $8.03
  • P/E Ratio
  • BMRN $19.20
  • ATI $31.48
  • Revenue Growth
  • BMRN 12.39
  • ATI 7.75
  • 52 Week Low
  • BMRN $50.76
  • ATI $39.23
  • 52 Week High
  • BMRN $73.51
  • ATI $103.64
  • Technical
  • Relative Strength Index (RSI)
  • BMRN 40.53
  • ATI 63.81
  • Support Level
  • BMRN $51.80
  • ATI $92.85
  • Resistance Level
  • BMRN $53.49
  • ATI $103.64
  • Average True Range (ATR)
  • BMRN 1.84
  • ATI 3.61
  • MACD
  • BMRN -0.08
  • ATI 0.23
  • Stochastic Oscillator
  • BMRN 12.58
  • ATI 71.29

About BMRN BioMarin Pharmaceutical Inc.

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.

About ATI ATI Inc.

ATI Inc supplies specialty metals to various end markets, including aerospace and defense, oil and gas, automotive, and electrical energy, among many others. The company's operating segment includes High-Performance Materials and Components and Advanced Alloys and Solutions. The majority of revenue is from the High-Performance Materials segment. The High-Performance Materials segment is focused on a wide range of high-performance specialty materials, parts, and components for several the majority of end markets, including the aerospace & defense, medical, and energy markets. Geographically, it operates in the United States, China, the United Kingdom, Germany, France, Canada, and Others, the majority is from the United States.

Share on Social Networks: